Alnylam Pharmaceuticals, Inc. (ALNY)
236.06
-0.16
(-0.07%)
USD |
NASDAQ |
Aug 24, 16:00
237.08
+1.02
(+0.43%)
After-Hours: 20:00
Alnylam Pharmaceuticals Gross Profit Margin (Quarterly) : 76.88% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 76.88% |
| March 31, 2026 | 81.91% |
| December 31, 2025 | 75.60% |
| September 30, 2025 | 83.98% |
| June 30, 2025 | 81.52% |
| March 31, 2025 | 88.04% |
| December 31, 2024 | 82.67% |
| September 30, 2024 | 82.85% |
| June 30, 2024 | 89.59% |
| March 31, 2024 | 86.65% |
| December 31, 2023 | 80.47% |
| September 30, 2023 | 88.77% |
| June 30, 2023 | 73.22% |
| March 31, 2023 | 82.82% |
| December 31, 2022 | 84.70% |
| September 30, 2022 | 84.44% |
| June 30, 2022 | 81.85% |
| March 31, 2022 | 83.29% |
| December 31, 2021 | 85.43% |
| September 30, 2021 | 82.59% |
| June 30, 2021 | 82.43% |
| March 31, 2021 | 82.51% |
| December 31, 2020 | 85.92% |
| September 30, 2020 | 82.68% |
| June 30, 2020 | 80.83% |
| Date | Value |
|---|---|
| March 31, 2020 | 86.63% |
| December 31, 2019 | 83.01% |
| September 30, 2019 | 92.56% |
| June 30, 2019 | 68.53% |
| March 31, 2019 | 53.27% |
| December 31, 2018 | 92.08% |
| September 30, 2018 | -63.51% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 90.21% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 96.13% |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| BridgeBio Pharma, Inc. | 93.68% |
| Pfizer Inc. | 62.94% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 109.1% |
| Return on Assets | 16.08% |
| Return on Invested Capital | 22.27% |
| Profit Margin (Quarterly) | 12.74% |
| Operating Margin (Quarterly) | 17.93% |
| Return on Net Operating Assets | 50.15% |